Keywords: جهش BRAF; Aggressive digital papillary adenocarcinoma (ADPA); comprehensive genomic profiling; BRAF mutation; therapeutic target
مقالات ISI جهش BRAF (ترجمه نشده)
مقالات زیر هنوز به فارسی ترجمه نشده اند.
در صورتی که به ترجمه آماده هر یک از مقالات زیر نیاز داشته باشید، می توانید سفارش دهید تا مترجمان با تجربه این مجموعه در اسرع وقت آن را برای شما ترجمه نمایند.
در صورتی که به ترجمه آماده هر یک از مقالات زیر نیاز داشته باشید، می توانید سفارش دهید تا مترجمان با تجربه این مجموعه در اسرع وقت آن را برای شما ترجمه نمایند.
Keywords: جهش BRAF; Brain metastases; Adenocarcinoma; Lung cancer; EGFR mutation; BRAF mutation;
Keywords: جهش BRAF; Malignant melanoma; Molecular pathology; Molecular genetics; BRAF mutation; Personalized medicine; Targeted therapy; KIT mutation
Dramatic clinical response following dabrafenib and trametinib therapy in a heavily pretreated low grade serous ovarian carcinoma patient with a BRAF V600E mutation
Keywords: جهش BRAF; Low grade serous ovarian cancer; BRAF mutation; Dabrafenib; Trametinib;
BRAF V600E Mutation in Papillary Thyroid Cancer and Its Effect on Postoperative Radioiodine (131I) Therapy: Should We Modify Our Therapeutic Strategy?
Keywords: جهش BRAF; BRAF mutation; Papillary thyroid cancer; Radioiodine therapy; Prognostic factor; Mutación BRAF; Cáncer papilar de tiroides; Terapia con 131I; Factor pronóstico;
Mutación del gen BRAF V600E en el cáncer papilar de tiroides y su efecto en la terapia con yodo radiactivo (131I) posquirúrgica: ¿deberÃamos modificar nuestra estrategia terapéutica?
Keywords: جهش BRAF; Mutación BRAF; Cáncer papilar de tiroides; Terapia con 131I; Factor pronóstico; BRAF mutation; Papillary thyroid cancer; Radioiodine therapy; Prognostic factor;
Impact of primary tumour location and RAS/BRAF mutational status in metastatic colorectal cancer treated with first-line regimens containing oxaliplatin and bevacizumab: Prognostic factors from the AIO KRK0207 first-line and maintenance therapy trial
Keywords: جهش BRAF; Colorectal cancer; Prognostic factors; Primary tumour location; RAS mutation; BRAF mutation; Bevacizumab; Overall survival; First-line therapy;
PD-L1 status does not predict the outcome of BRAF inhibitor therapy in metastatic melanoma
Keywords: جهش BRAF; Metastatic melanoma; PD-L1 expression; BRAF mutation; BRAF inhibitors; MEK inhibitors; Biomarker;
Aberrant expression of CD20 in thyroid cancer and its clinicopathologic significance
Keywords: جهش BRAF; Thyroid cancer; Papillary thyroid carcinoma; CD20; Immunohistochemistry; BRAF mutation;
Short communicationInvestigation of patterns of nodal metastases in BRAF mutant lung cancer
Keywords: جهش BRAF; Lung cancer; Adenocarcinoma; BRAF mutation; Lymphatic metastasis;
Radiogenomic evaluation of lung cancer - Are there imaging characteristics associated with lung adenocarcinomas harboring BRAF mutations?
Keywords: جهش BRAF; Lung carcinoma; BRAF mutation; Computed tomography; Radiogenomics;
ReviewThe mitogen-activated protein kinase pathway in melanoma part I - Activation and primary resistance mechanisms to BRAF inhibition
Keywords: جهش BRAF; Metastatic melanoma; MAP kinase pathway; BRAF mutation; PI3K pathway; Primary resistance to targeted therapy;
MAPK pathway in melanoma part II-secondary and adaptive resistance mechanisms to BRAF inhibition
Keywords: جهش BRAF; Metastatic melanoma; MAP kinase pathway; BRAF mutation; Secondary and adaptive resistance; Immune effects of BRAF inhibition;
Original ResearchClinical and molecular characterisation of hereditary and sporadic metastatic colorectal cancers harbouring microsatellite instability/DNA mismatch repair deficiency
Keywords: جهش BRAF; Microsatellite instability; Mismatch repair; Lynch syndrome; BRAF mutation; Immunotherapy; Colorectal cancer;
Investigation of BRAF mutation analysis with different technical platforms in metastatic melanoma
Keywords: جهش BRAF; MM; metastatic melanoma; real-time PCR; real-time polymerase chain reaction; IHC; immunohistochemistry; FFPE; formaldehyde fixed-paraffin-embedded; BRAF mutation; Real-time PCR; Pyrosequencing; Immunohistochemistry;
Clinical significance of BRAF V600E mutational status in capsular nevi of sentinel lymph nodes in patients with primary cutaneous melanoma
Keywords: جهش BRAF; Melanoma; Capsular nevus; Sentinel lymph node; BRAF mutation; Immunohistochemistry;
Neuroendocrine Differentiation of a Primary BRAF Mutant Colon Cancer in a Patient With a History of Hairy Cell Leukemia
Keywords: جهش BRAF; Adenocarcinoma; BRAF mutation; Colorectal cancer; HCL; Vasoactive intestinal peptide;
Clinical implications of the extent of BRAFV600E alleles in patients with papillary thyroid carcinoma
Keywords: جهش BRAF; Papillary thyroid cancer; BRAF mutation; Lymph node metastasis; Recurrence;
Prevalence of BRAF and NRAS mutations in cutaneous melanoma patients in Taiwan
Keywords: جهش BRAF; BRAF mutation; melanoma; NRAS mutation
BRAF and MAP2K1 mutations in Langerhans cell histiocytosis: a study of 50 cases
Keywords: جهش BRAF; Langerhans cell histiocytosis; Age; BRAF mutation; MAP2K1 mutation; Pyrosequencing; Immunohistochemistry;
BRAF mutation and anaplasia may be predictive factors of progression-free survival in adult pleomorphic xanthoastrocytoma
Keywords: جهش BRAF; Pleomorphic xantho-astrocytoma; Glioma; BRAF mutation; IDH1/2 mutation; Histone H3.3 mutation;
Predictive role of BRAF mutations in patients with advanced colorectal cancer receiving cetuximab and panitumumab: A meta-analysis
Keywords: جهش BRAF; BRAF mutation; Colorectal cancer; Meta-analysis; Cetuximab; Panitumumab;
FOLFOX4 Plus Cetuximab for Patients With Previously Untreated Metastatic Colorectal Cancer According to Tumor RAS and BRAF Mutation Status: Updated Analysis of the CECOG/CORE 1.2.002 Study
Keywords: جهش BRAF; BRAF mutation; Cetuximab; FOLFOX4; Metastatic colorectal cancer; RAS mutation;
Metaanalysis of BRAF mutations and clinicopathologic characteristics in primary melanoma
Keywords: جهش BRAF; Asians; BRAF mutation; melanoma; metaanalysis; race; systematic review; ALM; acral lentiginous melanoma; CI; confidence interval; CSD; chronic sun damage; I2; degree of inconsistency; LMM; lentigo malignant melanoma; NM; nodular melanoma; OR; odds ratio;
High-stage urachal adenocarcinoma can be associated with microsatellite instability and KRAS mutations
Keywords: جهش BRAF; Urachal carcinoma; Microsatellite instability; KRAS mutation; BRAF mutation; BRAF V600E; Cancer
What you are missing could matter: a rare, complex BRAF mutation affecting codons 599, 600, and 601 uncovered by next generation sequencing
Keywords: جهش BRAF; Personalized medicine; next generation sequencing; targeted therapies; BRAF mutation
BRAF V600E Mutation and Clonal Evolution in a Patient With Relapsed Refractory Myeloma With Plasmablastic Differentiation
Keywords: جهش BRAF; BRAF mutation; Multiple myeloma; Relapse; Refractory; Vemurafenib;
BRAF V600E-mutated lung adenocarcinoma with metastases to the brain responding to treatment with vemurafenib
Keywords: جهش BRAF; BRAF mutation; Lung adenocarcinoma; Brain metastasis; Vemurafenib; Non-small cell lung cancer; Targeted therapy;
The role of BRAF(V600E) mutation as poor prognostic factor for the outcome of patients with intrathyroid papillary thyroid carcinoma
Keywords: جهش BRAF; BRAF mutation; Thyroid cancer; Papillary thyroid carcinoma
BRAF genetic heterogeneity in papillary thyroid carcinoma and its metastasis
Keywords: جهش BRAF; BRAF mutation; Papillary thyroid carcinoma; Anaplastic thyroid carcinoma; Thyroid;
New IDH1 I113T mutation associated with BRAF V600E mutation: New driver of gliomagenesis?
Keywords: جهش BRAF; Glioma; Pleomorphic xanthoastrocytoma; BRAF mutation; IDH1 mutation;
Vemurafenib in patients with BRAFV600 mutation-positive melanoma with symptomatic brain metastases: Final results of an open-label pilot study
Keywords: جهش BRAF; BRAF mutation; BRAF inhibitor; Vemurafenib; Advanced melanoma; Symptomatic brain metastases; Safety; Tumour regression;
BRAF inhibitors in cancer therapy
Keywords: جهش BRAF; BRAF mutation; BRAF inhibitors; Cancer therapy; Resistance mechanisms; Combination therapy; EGFR; epidermal growth factor receptor; MAPK; mitogen-activated protein kinase; PI3K; phosphatidylinositol-4,5-bisphosphate 3-kinase; PFS; progression free surviva
Distribution of KRAS and BRAF mutations in Moroccan patients with advanced colorectal cancer
Keywords: جهش BRAF; BRAF mutation; KRAS mutation; Colorectal cancerMutation du BRAF; Mutation du KRAS; Cancer colorectal
Stage III & IV colon and rectal cancers share a similar genetic profile: a review of the Oregon Colorectal Cancer Registry
Keywords: جهش BRAF; Colorectal cancer; BRAF mutation; KRAS mutation; MET mutation; NRAS mutation; PIK3CA mutation
Detection of the BRAF V600E mutation in serous ovarian tumors: a comparative analysis of immunohistochemistry with a mutation-specific monoclonal antibody and allele-specific PCR
Keywords: جهش BRAF; Serous ovarian tumors; BRAF mutation; Immunohistochemistry; Allele-specific PCR
Amelanotic acral melanomas: Clinicopathological, BRAF mutation, and KIT aberration analyses
Keywords: جهش BRAF; acral melanoma; amelanotic acral melanoma; amelanotic melanoma; BRAF mutation; HMB-45; KIT mutation; prognosisAAM, amelanotic acral melanoma; AJCC, American Joint Committee on Cancer; PCR, polymerase chain reaction
Oncogene abnormalities in a series of primary melanomas of the sinonasal tract: NRAS mutations and cyclin D1 amplification are more frequent than KIT or BRAF mutations
Keywords: جهش BRAF; BRAF mutation; CCND1 amplification; Cyclin D1; NRAS; KIT; Primary malignant melanoma of sinonasal tract; Sinonasal melanoma
BRAF mutations in melanoma and colorectal cancer: A single oncogenic mutation with different tumour phenotypes and clinical implications
Keywords: جهش BRAF; BRAF mutation; Biomarkers; Genotype; Histotype; Melanoma; Colorectal cancer; BRAF inhibitors
Aberrant pattern of the cytokeratin 7/cytokeratin 20 immunophenotype in colorectal adenocarcinomas with BRAF mutations
Keywords: جهش BRAF; Colorectal carcinomas; Cytokeratin 7; Cytokeratin 20; BRAF mutation; Microsatellite instability
BRAF, GNAQ, and GNA11 mutations and copy number in pediatric low-grade glioma
Keywords: جهش BRAF; Pediatric; Low-grade glioma; BRAF mutation; Copy number variation; GNAQ/GNA11
Influence of anatomical subsite on the incidence of microsatellite instability, and KRAS and BRAF mutation rates in patients with colon carcinoma
Keywords: جهش BRAF; Colon carcinoma; Colonic subsite; MSI; KRAS mutation; BRAF mutation
BRAFV600E mutation does not serve as a prognostic factor in Korean patients with papillary thyroid carcinoma
Keywords: جهش BRAF; BRAF mutation; Papillary carcinoma; Thyroid; Prognosis;
The BRAFT1799A mutation confers sensitivity of thyroid cancer cells to the BRAFV600E inhibitor PLX4032 (RG7204)
Keywords: جهش BRAF; Thyroid cancer; PLX4032; RG7204; BRAF mutation; BRAF inhibitor; Genetic-dependent therapy
Melanoma maligno amelanótico en un ganglio de glándula parótida. Estudio clinicopatológico, inmunohistoquímico y molecular de un caso
Keywords: جهش BRAF; Melanoma; Parótida; Ganglio; Traslocación EWS; Mutaciones BRAFMelanoma; Parotid gland; Lymph node; EWS traslocation; BRAF mutation
Prognostic utility of BRAF mutation in papillary thyroid cancer
Keywords: جهش BRAF; BRAF mutation; Papillary thyroid cancer; Risk stratification; Prognosis; Molecular marker
Pharmacodynamic Characterization of the Efficacy Signals Due to Selective BRAF Inhibition with PLX4032 in Malignant Melanoma
Keywords: جهش BRAF; AKT; v-akt murine thymoma viral oncogene homolog; ANOVA; analysis of variance; ATCC; American Type Culture Collection; BRAF; v-raf murine sarcoma viral oncogene homolog B1; BRAFm; BRAF mutation; CKIT; v-kit Hardy-Zuckerman 4 feline sarcoma viral oncogene
Insights into the molecular function of the inactivating mutations of B-Raf involving the DFG motif
Keywords: جهش BRAF; BRAF mutation; B-RafV600E; B-RafD594V; B-RafG596R; Kinase activity; Molecular dynamics simulation
Incidentally simultaneous occurrence of RET/PTC, H4–PTEN and BRAF mutation in papillary thyroid carcinoma
Keywords: جهش BRAF; Papillary thyroid carcinoma; RET rearrangement; BRAF mutation; PTEN; Target therapy
Enhanced B-Raf protein expression is independent of V600E mutant status in thyroid carcinomas
Keywords: جهش BRAF; Thyroid carcinoma; B-Raf; Immunohistochemistry; BRAF mutation